Ardelyx Revenue and Competitors
Estimated Revenue & Valuation
- Ardelyx's estimated annual revenue is currently $24.6M per year.
- Ardelyx's estimated revenue per employee is $72,485
- Ardelyx's total funding is $61M.
Employee Data
- Ardelyx has 340 Employees.
- Ardelyx grew their employee count by 65% last year.
Ardelyx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant to President and CEO at Ardelyx, Inc. | Reveal Email/Phone |
2 | Chief Financial & Operations Officer | Reveal Email/Phone |
3 | Chief Human Resources Officer | Reveal Email/Phone |
4 | Executive Assistant to Chief Financial & Operations Officer, and Office Manager | Reveal Email/Phone |
5 | CFO | Reveal Email/Phone |
6 | VP, Access Strategies and Patient Services | Reveal Email/Phone |
7 | VP Quality Assurance | Reveal Email/Phone |
8 | VP, Marketing | Reveal Email/Phone |
9 | VP, Market Access | Reveal Email/Phone |
10 | VP Biometrics | Reveal Email/Phone |
Ardelyx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Ardelyx?
Ardelyx is focused on enhancing the way people with kidney and cardiovascular diseases are treated by developing innovative first-in-class medicines. Ardelyx's pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which the Company is preparing for NDA filing mid-year, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELAￃﾯￆﾒￂﾢ (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin Corporation in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.
keywords:Biotechnology
$61M
Total Funding
340
Number of Employees
$24.6M
Revenue (est)
65%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ardelyx News
Ardelyx logo Ardelyx, Inc. (NASDAQ:ARDX Get Rating) has received a consensus recommendation of Buy from the nine ratings firms that are...
WALTHAM, Mass., April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,...
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet...
FREMONT, Calif. and WALTHAM, Mass., Sept. 3, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, ...
Other Companies in Fremont
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $139.8M | 344 | 14% | N/A |
#2 | $80.3M | 357 | N/A | N/A |
#3 | $80.3M | 357 | 9% | N/A |
#4 | $130.9M | 361 | 1% | N/A |
#5 | $140.5M | 365 | 5% | N/A |